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ABSTRACT
Hypoxia-inducible factor-1α (HIF-1α) mediates the response to hypoxia or other 
stimuli, such as growth factors, including endothelin-1 (ET-1), to promote malignant 
progression in numerous tumors. The importance of cofactors that regulate HIF-
1α signalling within tumor is not well understood. Here we elucidate that ET-1/ETA 
receptor (ETAR)-induced pathway physically and functionally couples the scaffold 
protein β-arrestin1 (β-arr1) to HIF-1α signalling. In epithelial ovarian cancer (EOC) 
cells, ET-1/ETAR axis induced vascular-endothelial growth factor (VEGF) expression 
through HIF-1α nuclear accumulation. In these cells, activation of ETAR by ET-1, 
by mimicking hypoxia, promoted the nuclear interaction between β-arr1 and HIF-
1α and the recruitment of p300 acetyltransferase to hypoxia response elements on 
the target gene promoters, resulting in enhanced histone acetylation, and HIF-1α 
target gene transcription. Indeed, β-arr1-HIF-1α interaction regulated the enhanced 
expression and release of downstream targets, such as ET-1 and VEGF, required for 
tumor cell invasion and pro-angiogenic effects in endothelial cells. These effects were 
abrogated by β-arr1 or HIF-1α silencing or by pharmacological treatment with the 
dual ET-1 receptor antagonist macitentan. Interestingly, ETAR/β-arr1 promoted the 
self-amplifying HIF-1α-mediated transcription of ET-1 that sustained a regulatory 
circuit involved in invasive and angiogenic behaviors. In a murine orthotopic model 
of metastatic human EOC, treatment with macitentan, or silencing of β-arr1, inhibits 
intravasation and metastasis formation. Collectively, these findings reveal the 
interplay of β-arr1 with HIF-1α in the complexity of ET-1/ETAR signalling, mediating 
epigenetic modifications directly involved in the metastatic process, and suggest that 
targeting ET-1-dependent β-arr1/HIF-1α pathway by using macitentan may impair 
EOC progression.
INTRODUCTION
In epithelial ovarian cancer (EOC), the most lethal 
gynecological malignancy, the autocrine and paracrine 
loop mediated by the aberrant activation of the G protein 
coupled receptor (GPCR) endothelin A receptor (ETAR) 
by endothelin-1 (ET-1), elicits pleiotropic activities, 
including cell proliferation, survival, migration, epithelial 
mesenchymal transition (EMT), invadopodia formation, 
chemoresistance and neovascularization, through the 
activation of different signalling networks [1-4]. In 
addition, ET-1 is present at high levels in tumor ascites 
[5] and ETAR overexpression is associated with the 
acquisition of chemoresistance, EMT phenotype and 
poor prognosis [2, 4]. Concordantly, the Cancer Genome 
Atlas (TCGA) data confirmed that ETAR, and the miR30a 
that controls it, are associated with worse prognosis in 
high-grade serous ovarian cancers (HG-SOC) [6-8]. In 
these cells also ETBR appears to have tumor-promoting 
activity through evasion of immune response [1, 9], as 
well as angiogenic and lymphangiogenic responses on 
blood and lymphatic endothelial cells [10, 11]. Therefore 
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ETAR and ETBR represent key targets in cancer therapy, 
including EOC that can be targeted by the dual ETAR/
ETBR antagonist macitentan [1-3]. The various functions 
of GPCR are often mediated by the ability of β-arrestin1 
(β-arr1), ubiquitously expressed adaptor protein, to serve 
as signal transducer and scaffold molecule in different 
malignancies [1-3, 8, 12-20]. In this context, we have 
recently demonstrated the cross-talk between ET-1 
receptors and other tyrosine kinase receptors, in which 
β-arr1 serves as molecular platform in the cytoplasm, 
as in the ET-1-mediated transactivation of the epidermal 
growth factor receptor (EGFR) [21] and the vascular 
endothelial growth factor receptor (VEGFR) -3 and -2 
[2, 22], and in the nucleus to organize complex signalling 
network, leading to activation of β-catenin [2, 23] and NF-
κB [24] pathways. In particular, ETAR mediated nuclear 
β-arr1 recruitment might allow fine tuning of important 
signalling cascades, contributing to the overall tumoral 
response to ET-1 during metastatic progression. 
Hypoxia-inducible factor-1α (HIF-1α) is well known 
for being the transcriptional factor that allows cellular 
adaptation to hypoxia surrounding cancer tissues. At the 
same time, HIF-1α activation also reflects the activation of 
different signalling triggered by growth factor receptors, 
including GPCR. Under normoxic conditions, HIF-1α 
is hydroxylated at specific proline residues by prolyl 
hydroxylases (PHDs), tagging it for ubiquitination and 
subsequent degradation by the proteasome pathway 
[25]. The inhibition of prolyl hydroxylation resulted in 
the stabilization of HIF-1α, its nuclear translocation and 
heterodimerization with HIF-1β. The heterodimer then 
recruits the p300 acetyltransferase family of coactivators 
to form a functional transcription factor that binds to 
specific promoter regions, known as hypoxia-responsive 
elements (HRE), to induce transcription of downstream 
target genes involved in metastatization [25, 26]. HIF-
1α thus appear at the centerpiece of a signalling node by 
which tumor cells take control of their invasive behaviour 
according to their microenvironment and growth factor 
context [27]. ET-1, mimicking hypoxia, through the 
binding with its GPCR, inhibits PHD2 to enhance HIF-
1α stabilization and transcriptional activity in different 
tumors and microenvironmental cells [1, 28, 29]. Because 
overexpression of HIF-1α in human tumors is associated 
with poor prognosis and treatment failure [30], the 
identification of the cofactors that trigger an epigenetic 
regulation of HIF-1α is mandatory to exploit tumor cell 
vulnerabilities. 
Understand how GPCR propagate pleiotropic 
signals to generate functionally selective responses in 
a β-arr1-dependent manner by interacting with distinct 
determinants, could help to dissect the β-arr1 transducer 
contribution to GPCR signaling. Through mechanisms not 
completely defined, β-arr1 has been found to physically 
interact with HIF-1α in the nucleus of breast and prostate 
cancer cells under hypoxia stimuli [31, 32]. However, 
besides hypoxic stimulus, the mechanisms underpinning 
whether and how β-arr1 gets into the nucleus to control 
HIF-1α transcription remain to be elucidated. 
To dissect the intricate interplay between β-arr1 
to HIF-1α, here we examined whether in response to 
ETAR, β-arr1 could function as a nuclear cofactor by 
recruiting HIF-1α on specific target gene promoters 
to activate transcription, including the involvement of 
histone acetylation for regulating metastatic process. We 
report a novel β-arr1-mediated epigenetic mechanism in 
controlling HIF-1α activity to promote the expression 
of proangiogenic downstream genes, ET-1 and VEGF, 
directly involved in tumor cell invasion and endothelial 
cell activities, offering the possibility to impair ETAR/ 
β-arr1/HIF-1α mediated EOC progression. 
RESULTS
ET-1/ETAR induces VEGF release through HIF-
1α that is blocked by macitentan
In EOC, VEGF has been reported to be a major 
mediator of ascites formation, invasiveness and metastatic 
dissemination, and is thereby associated with poor patient 
prognosis [33, 34]. We previously demonstrated that 
in normoxic condition ET-1 stimulates the secretion of 
VEGF in EOC cells [35]. Here we assessed the effect of 
ET-1 in the presence of the dual ET-1 receptor antagonist 
macitentan in HEY and 2008 cells, which express 
elevated levels of ET-1, ETAR and the nuclear-cytoplasmic 
scaffold protein β-arr1 (Supplementary. Figure S1). After 
incubation with ET-1, VEGF transcript levels were 
stimulated to an extent comparable with that induced by 
hypoxia, a recognized potent stimulus of VEGF (Figure 
1A). Similarly, analysis of conditioned media of EOC 
cells cultured in normoxic conditions showed that ET-1 
significantly increased VEGF release (up to 2.2 fold 
above control) (Figure1B). The treatment with macitentan 
strongly reduced VEGF expression at mRNA and protein 
levels (Figure 1A, 1B).
Having VEGF the hypoxic responsive elements 
(HRE) capable to bind HIF-1α on its promoter, we 
evaluated whether HIF-1α was involved in the ET-
1-dependent induction of VEGF in EOC cells. The 
silencing of HIF-1α, as well as macitentan treatment, 
resulted in a significant reduction in the capacity of ET-1 
to increase VEGF protein expression (Figure 1C and 
Supplementary Figure S2A, S2B). These data suggest the 
intriguing hypothesis that ET-1/ETAR axis shares similar 
transcriptional properties with hypoxia to sustain HIF-
1α-mediated VEGF release in EOC cells, which can be 
inhibited by macitentan. 
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Nuclear β-arr1 interacts with the transcriptional 
factor HIF-1α upon ETAR activation in EOC cells
Because β-arr1 is emerging as key determinant 
of different malignances to promote invasiveness and 
metastasis [1, 3, 14-16, 21-24, 31, 32, 36, 37] a better 
understanding of its upstream regulators and downstream 
effectors will be essential for design of innovative cancer 
treatments.
To investigate whether β-arr1 could act as nuclear 
scaffold to regulate HIF-1α transcriptional activity, we first 
examined the nucleo-cytoplasmic shuttling and interaction 
of both β-arr1 and HIF-1α proteins in EOC cells, 
endogenously expressing both proteins, upon different 
times of ET-1 treatment (Figure 2A and Supplementary 
Figure S2A, S2B). Immunoblotting analysis showed 
that β-arr1 translocated to the nuclear compartment 
after ET-1 stimulation in a time-dependent manner. 
Nuclear accumulation of endogenous β-arr1 and HIF-1α 
increased after 2 hours of ET-1 challenge demonstrating 
that following ET-1 stimulation both HIF-1α and β-arr1 
proteins accumulate in the nucleus. As shown in Figure 
2B, HIF-1α was detected in β-arr1 immunoprecipitates 
isolated from the nuclei of ET-1-treated HEY and 2008 
cells, but not in IP with control IgG, demonstrating the 
nuclear association between β-arr1 and HIF-1α. This 
association was inhibited by macitentan in both cell lines 
(Figure 2B). Similarly, when we transfected HEY cells 
with β-arr1Q394L mutant, in which we introduce the 
nuclear export signal by a single point mutation (Q394L), 
we observed that this mutant did not co-IP with HIF-1α 
(Figure 2C), indicating that ETAR activation promotes 
nuclear accumulation of β-arr1 and HIF-1α that directly 
interact in EOC cells. 
ETAR-induced nuclear β-arr1/HIF-1α interaction 
mediates histone acetylation and target gene 
activation
To further analyze the functional role of β-arr1 and 
HIF-1α nuclear interaction, we analyzed how β-arr1 could 
Figure 1: HIF-1α mediates ET-1/ETAR axis-induced VEGF expression that is inhibited by macitentan in EOC cells. 
A. HEY and 2008 EOC cells were cultured in serum free-media under normoxic or hypoxic conditions for 24 h or treated with ET-1 in the 
absence or in the presence of macitentan (MAC), and VEGF mRNA expression was analyzed by qPCR. Bars are means ±SD from three 
independent experiments each performed in triplicate. *, p < 0.01 versus CTR; **, p < 0.01 versus ET-1. B. HEY and 2008 cells were 
stimulated with ET-1 in the absence or in the presence of MAC. VEGF protein secretion was analyzed by ELISA in EOC cell conditioned 
media collected after 24 h. Bars are means ±SD from three independent experiments each performed in triplicate. *, p < 0.01 versus CTR; 
**, p < 0.001 versus ET-1. C. HEY cells were transfected with SCR or siRNA against HIF-1α and stimulated with ET-1 in the absence or 
in the presence of MAC. VEGF protein levels were analyzed by immunoblotting (IB).Tubulin was used as loading control. Densitometric 
analysis (right panel) of VEGF protein bands from three independent experiments, normalized to tubulin content. Bars are means ±SD. *, 
p < 0.01 versus CTR; **, p < 0.001 versus ET-1.
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be recruited with HIF-1α on selective promoter target 
genes, influencing their transcription. To date, β-arr1 has 
not been reported to bind directly DNA, but it can interact 
with transcription factors [32]. Based on the report that 
β-arr1 interacts with HIF-1α in breast cancer cells [31], 
Zecchini et al., have carried out the genome wide-map 
of β-arr1 transcriptome in prostate cancer cells reporting 
binding sites for β-arr1, p300 and HIF-1α on the regulatory 
regions of target gene promoter in these cancer cells under 
hypoxic or pseudohypoxic conditions [32]. 
Given the role of nuclear β-arr1 to regulate gene 
transcription in tumor cells upon GPCR activation [2, 
15, 16, 23, 24, 31, 32, 37], we investigated whether 
the enhanced nuclear recruitment of β-arr1 in ET-1-
stimulated EOC cells could result in the upregulation 
of HIF-1α target genes, VEGF and ET-1. Because ET-1 
promoter shares similar transcription properties with 
VEGF promoter, having three HIF-1α consensus binding 
sites [38], we evaluated whether ET-1 can be a β-arr1/
HIF-1α transcriptional target, by performing chromatin 
immunoprecipitation (ChIP) assays on ET-1 promoter. 
In particular using a primer set designed to amplify the 
active HRE at -118 to -125 bp upstream the transcription 
start site of ET-1 promoter, we demonstrated that both 
β-arr1 and HIF-1α were recruited, in a time dependent 
manner, on HRE of ET-1 promoter upon ET-1 stimulation 
(Figure 3A). As in EOC cells, both β-arr1 [23] and HIF-
1α [39] have been previously shown to interact with p300, 
we assessed the involvement of β-arr1 in controlling 
histone acetylation. As expected, ChIP analysis of ET-
1-HRE region showed the recruitment of p300 and an 
enhanced acetylation in histone 3 at this promoter upon 
ET-1 challenging. All these recruitment were impaired in 
EOC cells treated with macitentan (Figure 3B). A similar 
effect was also found for VEGF promoter (Figure 3C). To 
further investigate the mechanism by which the interaction 
between β-arr1 and HIF-1α leads to an increase of HIF-1α 
transcriptional activity, we assessed whether β-arr1 could 
form a complex with p300 and HIF-1α. The silencing of 
β-arr1 prevented the formation of β-arr1/ HIF-1α/p300 
transcriptional complex on ET-1 promoter (Figure 3D) 
indicating that β-arr1 may provide a nuclear anchor for 
HIF-1α and p300, required for the epigenetic regulation 
promoted by the ET-1/ETAR axis. Consistent with these 
results, the silencing of β-arr1 or the treatment with 
macitentan, strongly inhibited the expression of HIF-
1α target genes, ET-1 and VEGF, as analyzed by qPCR 
(Figure 3E). These results indicate that β-arr1 and p300 
are two new components required for nuclear HIF-1α 
function, in response to ET-1 stimulus. 
ETAR-induced nuclear β-arr1/HIF-1α interaction 
promotes transcriptional activity
Next, we assessed the effects of gain-loss of 
function of β-arr1 on HIF-1α-dependent transcriptional 
activity by using a HRE report construct containing three 
functional HRE, upstream the luciferase reporter gene. 
As shown in Figure 4A, in HEY cells cultured under 
Figure 2: Nuclear β-arr1 interacts with HIF-1α in EOC cells upon ETAR activation. A. Cytoplasmic and nuclear extracts of 
HEY cells, treated with ET-1 for the indicated times, were IB with anti- β-arr1 or with anti-HIF-1α. Tubulin and histone 3 (H3) were used 
as loading cytoplasmic or nuclear control, respectively. B. Nuclear extracts of HEY and 2008 cells treated with ET-1 and/or MAC for 2 h 
were immunoprecipitated (IP), with anti- β-arr1 (left panel) or with irrelevant anti-IgG (negative control) (right panel) and IB with HIF-1α 
or β-arr1 antibodies (Abs). H3 was used as loading nuclear control. C. HEY cells expressing β-arr1-FLAG or β-arr1Q394L-FLAG were 
treated with ET-1 for 2 h and nuclear fractions were IP with anti-FLAG or with anti-IgG, and IB with anti-HIF-1α or anti-FLAG Abs. H3 
was used as loading nuclear control.
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normoxic condition ET-1 treatment, or reduced oxygen 
levels (1%), significantly increased the HRE report 
activity, thus highlighting the ability of ET-1 to mimic 
the hypoxia-mediated HIF-1α transcription. This increase 
was not observed in cells silenced for β-arr1, suggesting 
a positive regulatory role of β-arr1 in ET-1-mediated 
HIF-1α transcriptional activity (Figure 4A). To establish 
whether the nuclear β-arr1/HIF-1α interaction, following 
ET-1 stimulation, could affect HIF-1α transcriptional 
activity, we performed reporter assay of ET-1 and VEGF. 
In particular, we used a human ET-1 promoter reporter 
sequence, spanning -1300 to +230 bp surrounding the 
transcriptional initiation site, containing the functional 
HRE and a luciferase reporter system with five HRE 
derived from 5’-untranslated region of human VEGF. 
As expected, treatment of cells with ET-1 significantly 
increased ET-1 (Figure 4B) and VEGF (Figure 4C) 
promoter activity. A significant decrease was observed 
in cells silenced for β-arr1 or HIF-1α, or treated with 
macitentan (Figure 4B, 4C), indicating that tumor cells 
require the association of HIF-1α with β-arr1 for a full 
transcriptional response to ET-1/ETAR axis. In line with 
these results, we evaluated the secretion of ET-1 and 
VEGF. Analysis of conditioned media collected from 
EOC cells, showed that the treatment with macitentan, 
as well as HIF-1α silencing, significantly decreased the 
basal ET-1 secretion, thus blocking the autocrine ET-1 
self-amplifying positive loop of HIF-1α-ET-1 (Figure 
5A). Moreover a significant decrease in the ET-1 release 
was observed in EOC cells stably silenced with sh-β-
arr1 (Figure 5B), and this effect was rescued by the re-
expression of β-arr1, but not by β-arr1Q394L (Figure 5B). 
Figure 3: ET-1/ETAR stimulates the recruitment of β-arr1, HIF-1α and p300 on the promoter of ET-1 and VEGF target 
genes. A. HEY cells were treated with ET-1 for indicated times and the binding of HIF-1α or β-arr1, to ET-1 promoter region was measured 
by ChIP assays followed by PCR. HEY cells were treated with ET-1 and/or MAC for 2 h and the binding of HIF-1α or β-arr1, or p300, or 
acetylated histone 3 (AcH3) to ET-1 promoter B. or to VEGF promoter C. region was measured by ChIP assays followed by PCR. D. HEY 
cells were transfected with SCR or si- β-arr1 and treated with ET-1 for 2 h and the binding of β-arr1, HIF-1α, AcH3, and p300 to ET-1 
promoter region was measured by ChIP assay followed by PCR. Non-specific IgG was used as the irrilevant antibody (IRR) for all ChIP 
reactions. The input DNA lane represents one- twentieth of the precleared chromatin used in each ChIP reaction. E. qRT-PCR analysis of 
ET-1 and VEGF expression in HEY cells transfected with SCR or si- β-arr1 and stimulated with ET-1 and/or MAC. Bars are means ±S.D 
from three independent experiments each performed in triplicate; *, p < 0.002 versus CTR transfected cells; **, p < 0.001 versus ET-1.
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Similarly, VEGF secretion, which was induced by ET-1, 
was strongly reduced both in cells silenced for HIF-1α 
or β-arr1. In these latter silenced cells the reintroduction 
of β-arr1, but not of β-arr1Q394L, was able to reproduce 
the ability of EOC cells to secrete VEGF (Supplementary 
Figure S3), indicating that nuclear β-arr1 might induce 
autocrine production of ET-1, that, in turn, may sustain 
HIF-1α-mediated VEGF secretion. Altogether, these 
findings demonstrated that ET-1 acts through ETAR to 
enhance the recruitment of p300 and β-arr1 with HIF-1α. 
The formation of this nuclear complex increases histone 
acetylation in specific chromosomal regions to promote 
gene transcription, which is most likely the mechanism 
upregulating ET-1 and VEGF expression. 
β-arr1/HIF-1α-mediated ET-1 and VEGF released 
by EOC cells enhance angiogenic functions in 
endothelial cells
To determine how β-arr1/HIF-1α can regulate the 
secretion of pro-angiogenic factors, as VEGF and ET-
1, to stimulate endothelial cell functions, we monitored 
human umbilical vein endothelial cells (HUVEC) ability 
to migrate and form tube-like structures in response to 
conditioned media (CM) from HEY cells. HUVEC cells 
plated in serum-free medium showed a low capacity to 
migrate (Figure 6A) and to form small tight clusters with 
few sprouting and elongation (Figure 6B-6D). In the 
presence of HEY CM, HUVEC increased their migration 
and displayed increased network formation (Figure 6). 
Next we evaluated the contribution of ET-1, as well as of 
β-arr1 and HIF-1α in the activation of HUVEC functions. 
Figure 4: β-arr1 associates with HIF-1α to mediate HIF-1α dependent transcriptional activity. A. HIF-1α transcriptional 
activity evaluated in HEY cells cultured under normoxic or hypoxic conditions for 24 h and transfected with SCR or si-β-arr1 and stimulated 
with ET-1. Bars are means ±SD from three independent experiments each performed in sextuplicate; *, p < 0.01 vs SCR-CTR; **, p < 0.05 
vs ET-1. B. ET-1 and C. VEGF promoter activity evaluated in HEY cells transfected with SCR or si-β-arr1 or si-HIF-1α and treated with 
ET-1 and/or MAC for 2 h. Bars are means ±SD from three independent experiments each performed in triplicate; *, p < 0.05 vs SCR-CTR; 
**, p < 0.05 vs ET-1.
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EOC cell CM-induced migration (Figure 6A) and tube-
like structure formation (Figure 6B-6D) in HUVEC were 
inhibited by pre-treated with macitentan, capable to block 
ETBR expressed in endothelial cells. Moreover, CM from 
EOC cells silenced for β-arr1 or HIF-1α was unable to 
induce HUVEC migration and cord formation (Figure 
6). These results demonstrated that EOC cells are able to 
release ET-1 and VEGF that induce angiogenic properties 
in endothelial cells and that nuclear β-arr1/HIF-1α 
complex is required to increase this paracrine regulation. 
Interestingly, these data provide evidence that macitentan 
might block ET-1 promoting effects by targeting EOC 
cells, mainly expressing ETAR, and endothelial cells, 
expressing ET BR. 
Nuclear β-arr1 and HIF-1α are required for ET-1/
ETAR axis mediated invasiveness, intravasation 
and metastasis
Next, we evaluated whether nuclear β-arr1 can 
cooperate with HIF-1α to drive an invasive program. 
As shown in Figure 7A and Supplementary Figure S2B, 
the loss of β-arr1 or HIF-1α, as well as the treatment 
with macitentan, abolished the ET-1-stimulated cell 
invasiveness. Most importantly the re-expression of 
β-arr1, but not mutant β-arr1Q394L, was able to rescue 
the ability of EOC cells to invade, highlighting the role 
of ETAR-induced β-arr1-HIF-1α nuclear complex in 
promoting pro-invasive program.
To evaluate whether nuclear β-arr1 is required 
for metastatic progression in vivo, we orthotopically 
implanted HEY cells or HEY cells stably silenced for 
β-arr1 and/or re-expressing β-arr1 or mutant β-arr1Q394L, 
into the peritoneal cavity of nude mice. Metastatic 
intraperitoneal (i.p.) spread was detected on the peritoneal 
surface, omentum, mesentery, small bowel and ovaries 
(Figure 7B). In parallel, other two groups of mice were 
i.p. injected with HEY cells, and after two weeks were 
treated with vehicle (CTR) or macitentan (30mg/kg, oral 
daily) for 4 weeks. The treatment with macitentan, capable 
of targeting aggressive EOC cells and tumor-associated 
endothelial cells [2, 3, 40-43] significantly decreased the 
number of visible metastatic lesions in EOC xenografts 
(Figure 7B). Silencing of β-arr1 significantly inhibited 
metastasis formation. Interestingly, the re-expression 
of β-arr1 was able to increase the number of metastatic 
nodules, but not the re-expression of β-arr1Q394L 
(Figure 7B), confirming in vivo that nuclear accumulation 
of β-arr1 is a key event in ET-1/ETAR-promoted EOC 
metastatic progression. 
During metastases, EOC cells acquire the ability 
to invade hematogenously surrounding tissues and 
intravasate [44]. To evaluate whether β-arr1 silencing 
might impair EOC cell intravasation, the presence of 
circulating tumor cells was assessed by measuring the 
relative expression of human specific GAPDH in blood 
from different groups of mice. Notably, the silencing of 
β-arr1 significantly diminished the presence of circulating 
tumor cells, which was not rescued when β-arr1Q394L 
was re-expressed (Figure 7C). These findings demonstrate 
the functional role of nuclear β-arr1 in EOC cell 
intravasation and metastatic diffusion.
Figure 5: ET-1 secretion by EOC cells requires β-arr1 and HIF-1α. A. ET-1 protein secretion evaluated by ELISA in conditioned 
media of HEY cells cultured for 24 h and transfected with SCR or si-β-arr1 or si-HIF1α and/or treated with MAC. Bars are means ±SD of 
three independent experiments each performed in triplicate; *, p < 0.01 versus CTR. B. Conditioned media of HEY cells stably expressing 
sh-SCR or sh-β-arr1, and rescued with β-arr1 or β-arr1Q394L expression vectors were evaluated for ET-1 protein secretion by ELISA. Bars 
are means ±SD from three independent experiments each performed in triplicate; *, p < 0.001 versus SCR; **, p < 0.05 versus sh-β-arr1.
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Figure 6: ET-1 and VEGF released by EOC cells influence migration and capillary-like structure formation in 
endothelial cells. A. HUVEC cells were seeded on serum-free media in the absence (CTR), and stimulated with conditioned media (CM) 
from HEY cells untrasfected or transfected with siRNA against HIF-1α or β-arr1, in presence or absence of MAC and cell migration assay 
was performed. Representative images of migrating HUVEC (upper panels). Bars are means ±SD from three independent experiments 
each performed in triplicate. *, p < 0.05 versus untreated cells (CTR); **, p < 0.002 versus CM of HEY cells. B. Cord formation was 
examined and quantification analysis was performed by measuring tubule length C. and number of intersections D.. Representative images 
of HUVEC forming tubule-like structures (upper panels). Bars are means ±SD from three independent experiments each performed in 
triplicate. *, p < 0.01 versus CTR; **, p < 0.001 versus CM from HEY cells.
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DISCUSSION
Aberrant activation of autocrine and paracrine 
signalling by ET-1 binding to its receptors, regulates 
pleiotropic functions, including the dynamic interactions 
between the tumor cells and the host microenvironment 
to stimulate metastatic dissemination. Among tumor-
secreted angiogenic molecules, VEGF and ET-1 are 
particularly involved in the reciprocal exchanges between 
malignant cells and endothelial cells within hypoxic 
microenvironment, via HIF-1α [1]. Therefore the 
identification of key cofactors of HIF-1α that could activate 
complex tumor and angiogenic responses might help in the 
development of more efficacious antitumoral treatment. 
In this study we report that ETAR/β-arr1 is a critical 
driver of EOC progression linking HIF-1α signaling. Our 
findings provide evidence that activation of ETAR by ET-1 
promotes a direct nuclear interaction between β-arr1 and 
HIF-1α to trigger epigenetic modification endowing EOC 
cells with invasive properties and capabilities to release 
angiogenic factors. The wide spread involvement of β-arr1 
in the regulation of different genes in tumors [1, 2, 15, 
16, 23, 24, 31, 32, 37], by forming nuclear complexes 
with different transcription factors or epigenetic modifier, 
Figure 7: ETAR/β-arr1 driven HIF-1α signalling sustains invasion, intravasation and metastasis formation. A. Cell 
invasion assay was performed in 2008 cells, transfected with SCR, si-HIF-1α, si-β-arr1 or si-β-arr1 rescued with β-arr1 or β-arr1Q394L 
expression vectors. ET-1 in the absence or presence of MAC were used as chemoattractant. Bars are means ±SD from three independent 
experiments each performed in triplicate; *, p < 0.05 versus SCR-CTR; **, p < 0.002 versus SCR-ET-1; ***, p < 0.001 versus si-β-arr1; 
****, p < 0.005 versus si-β-arr1 and ET-1. Representative images of invading cells (right panels). B. Female nude mice were injected 
into the peritoneal cavity with HEY cells or HEY cells stably expressing sh-SCR (SCR), or sh-β-arr1, or sh-β-arr1 rescued with β-arr1 or 
β-arr1Q394L expression vectors. Two weeks after tumor cell injection, two groups of mice injected with untransfected HEY cells, were 
treated with vehicle control (CTR), or MAC (30 mg/kg oral daily) for 4 weeks. All mice were euthanized and intraperitoneal organs were 
examined for visible metastases (right panel, white arrows). Bars are means ±SD of ten mice for group from three independent experiments. 
*, p < 0.001 versus CTR mice; **, p < 0,002 versus sh-SCR expressing mice; ***, p < 0,001 versus sh-β-arr1 expressing mice. C. Blood 
from mice i.p. injected with HEY cells stably expressing sh-SCR (SCR) or sh-β-arr1, or rescued with β-arr1Q394L expression vector was 
isolated and red blood cells lysed. The presence of circulating tumor cells was assessed as a function of human-specific GAPDH expression 
relative to murine β-actin. Bars are means ±SD of ten mice for group; *, p < 0,002 versus sh-SCR expressing mice; **, p < 0,001 versus 
sh-β-arr1 expressing mice.
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suggest that β-arr1-mediated complex may represent 
a critical end-point capable of shaping the functional 
selectivity of GPCR. Previous studies demonstrate 
that β-arr1 interacts with HIF-1α in breast and prostate 
cancer cells under hypoxic condition [31-32]. Our data 
complement and add greater relevance to these studies, 
demonstrating that activation of the GPCR, ETAR, by its 
ligand ET-1, by mimicking hypoxia, promotes a nuclear 
association between β-arr1 and HIF-1α on the HRE 
binding sites. Indeed we reveal that in response to GPCR 
activation β-arr1 could control two aspects of HIF-1α 
nuclear functions: nuclear accumulation and assembly 
of a transcriptional complex. Consistent with a role of 
co-pilot to organize nuclear complex, β-arr1 promotes 
the recruitment of p300 with HIF-1α on ET-1 proximal 
promoter, and histone modification associated with ET-1 
gene transcription. Of interest, our findings support a 
positive feedback mechanism in which ET-1, that is able 
to stabilize HIF-1α promotes the autoregulatory HIF-1α-
mediated transcription of ET-1 itself that, in turn, sustains 
tumor cell invasion, and angiogenic effects on surrounding 
endothelial cells (Figure 8). Hence, one can envisage that 
β-arr1-mediated interplay represents the initial scaffold 
on which transcriptional regulatory complexes could 
be built to regulate pleiotropic activities and functional 
selective responses of GPCR in different malignancies. 
In this context, we recently reported that ETAR/β-arr1 co-
opts Wnt/β-catenin signaling, through a self-strengthening 
feedback loop [2], suggesting that β-arr1 complexes can 
recruit distinct factors that enhance the transcription of 
specific target genes orchestrating a network that promotes 
cell migration, intravasation and metastasis formation.
Emerging evidence supports the hypothesis 
that factors released by tumor cells may modify the 
microenvironment within the vascular system, providing 
a favorable niche for tumor progression [45]. Our data 
Figure 8: A schematic model describing the potential mechanism by which β-arr1 regulates ET-1/ETAR-induced HIF-
1α transcriptional activity. In EOC cells ET-1 binding on ETAR leads to recruitment of β-arr1. Then β-arr1 shuttles into the nucleus, 
where it interacts with HIF-1α to form a transcriptional complex with p300 required for histone acetylation and for the transcription of 
HIF-1α target genes, such as ET-1 and VEGF. This mechanism, also induced by hypoxia, leading to the amplification of the ET-1 autocrine 
loop, can be blocked by the approved small molecule macitentan impairing invasion, angiogenesis and metastatic spread in EOC.
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extend those in earlier report [46] suggesting that ET-
1, together with VEGF, represents one of such factors 
that mediate the communication between tumor and 
endothelial cells, favoring a permissive environment 
for metastatic spread. At mechanistic level, we found 
that silencing of HIF-1α or of β-arr1 completely inhibit 
angiogenic functions in endothelial cells induced by 
factors secreted by EOC cells. Moreover β-arr1 knock-
down hampers the release of tumor cells into the 
circulation and metastatic dissemination, underlying 
the pathobiological relevance of nuclear β-arr1/HIF-
1α-transcriptional mechanism. Therefore the discovery 
of other upstream inputs, such as ET-1/ETAR, greatly 
expanded the complexity of β-arr1/HIF-1α regulation 
and the repertoire of possible therapeutic intervention. 
Interestingly, immunohistochemical analysis of human 
tissues demonstrated that the majority of β-arr1-
positive HG-SOC were positive for ETAR, whereas 
no low grade coexpressed β-arr1 and ETAR [21], 
suggesting that coexpression of β-arr1 and ETAR 
may be indicative of the malignant phenotype. The 
approved dual ETAR/ETBR antagonist macitentan, by 
impairing the nuclear translocation of β-arr1 and HIF-
1α transcriptionally activity, inhibits cell invasion and 
metastatic dissemination, as well as intravasation [2]. 
Most importantly, our findings reveal the opportunity 
of macitentan to interfere with two compartments, 
hampering the communication between endothelial 
cells and surrounding tumor cells. In conclusion, we 
dissect a nuclear interaction of β-arr1 in mediating ET-1/
ETAR-induced HIF-1α responses, showing that nuclear 
β-arr1-mediated regulatory complex could represent a 
barcode required to enhance the transcription of specific 
target genes that orchestrate the intricate autocrine and 
paracrine ET-1/ETAR signalling network and interaction 
with tumor microenvironment. Blockade of ET-1 axis by 
macitentan, may represent a new opportunity for improved 
therapeutics in EOC by targeting ET-1 receptors expressed 
on both tumor and stromal compartment. 
MATERIALS AND METHODS
Cells and cell culture conditions
Established human ovarian serous adenocarcinoma 
cell lines, HEY, obtained from the American Type 
Culture Collection (LGC Standards, Teddington, UK), 
and 2008, provided by Dr SB Howell (University of San 
Diego, La Jolla, CA, USA) were cultured as previously 
described [3] and passed in our laboratory for fewer than 
three months after resuscitation. HUVEC (Promocell, 
Heidelberg, Germany) were grown in endothelial basal 
medium-2 (Lonza, Basel, Switzerland) containing 10% 
heat-inactivated fetal bovine serum supplemented with 
endothelial growth media-2 single quote (Lonza). Cells 
were tested routinely for cell proliferation, as well as 
mycoplasma contamination, and they showed similar 
growth rate and negative mycoplasma during the 
experiments. Cells were serum starved by incubation 24 h 
in serum-free medium prior to each experiment with ET-1. 
To expose cells to hypoxia, a modular incubator was used 
with an atmosphere setting of 5% CO2, 95% N2, and 1% 
O2. ET-1 was used at 100 nM and was purchased from 
Bachem. Macitentan (MAC), also called ACT-064992 or 
N-(5-[4-bromophenyl]-6-{2-[5-bromopyrimidin-2-yloxy]
ethoxy}pyrimidin-4-yl)-N’-propylsulfamide, was added 
30 min before the ET-1 at a dose of 1 µM and was kindly 
provided by Actelion Pharmaceuticals, Ltd (Switzerland). 
Immunoblotting and immunoprecipitation
Whole cell lysates were prepared using a modified 
RIPA buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 
1% Triton X-100, 1% sodium deoxycholate, 0.1% 
SDS) containing a mixture of protease and phosphatase 
inhibitors. NE-PER nuclear and cytoplasmic extraction 
reagents (Thermo Scientific, IL, USA) were used to 
separate cytoplasmic and nuclear fractions. Protein 
content of the extracts was determined using the Bio-Rad 
protein assay kit (CA, USA). For the immunoprecipitation 
(IP), the nuclear extracts were treated with 15 μg/ml of 
DNase I (Life Technologies, Italy) and precleared cell 
lysates were incubated with DYDDDK (FLAG) (Cell 
Signaling, MA, USA) or β-arr1 or control IgG (Santa 
Cruz Biotechology, CA, USA) antibodies (Abs) and 
protein G-agarose beads (Thermo Scientific, IL, USA) at 
4 °C overnight. Cell lysates or immunoprecipitates were 
resolved by SDS-PAGE and the interacting proteins were 
detected by immunoblotting (IB) with the following Abs: 
HIF-1α (Abcam, UK), β-arr1 (Santa Cruz Biotechology, 
CA, USA), Histone 3 (BD Laboratory Transduction, NJ, 
USA), α-tubulin (Santa Cruz Biotechnology, CA, USA), 
VEGF (Abcam, UK). To obtain clean and specific IB 
signals of β-arr1 or β-arr1-FLAG which run very close to 
heavy chain of IgG, we used HRP-conjugated protein A 
(Thermo Scientific, IL, USA) instead of HRP-conjugated 
secondary Ab. Blots were developed with the enhanced 
chemiluminescence detection system (ECL; Thermo 
Scientific, IL, USA). 
RNA isolation and qPCR
Total RNA was extracted using the Trizol 
reagent (Life Technologies, Italy) according to the 
manufacturer’s protocol. First-strand complementary 
DNA was synthesized using SuperScript® VILO™ 
cDNA synthesis kit (Life Technologies, Italy). qPCR 
was performed using Power SYBR Green PCR 
Master Mix (Life Technologies, Italy) with a 7500 
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Fast real-Time PCR System (Life Technologies, Italy) 
according to the manufacturer’s instructions. The 
expression levels of VEGF and ET-1 were determined 
by normalizing to cyclophilin-A mRNA expression. 
The primers employed for qPCR were as follows: 
VEGF Fw: 5’- CCTCAGTGGGCACACACACTCC-3’ 
and Rev: 5’-CGAAACCATGAACTTTCTGC-3’; 
ET-1 Fw: 5’-GCGTCCTCGTTCAAAACATT-3’ and 
Rev: 5’-CAGAAACTCCACCCCTGTGT-3’; HIF-
1α: Fw: 5’-CAAGTCACCACAGGACAG-3’ and 
Rev: 5’- AGGGAGAAAATCAAGTCG -3’; β-arr1 
Fw: 5’- CAGTATGCAGACATCTGCCTTT-3’ and 
Rev: 5’-AGTTCGTGTCTTCGTGCT-3’; ETAR Fw: 
5’-GGGATCACCGTCCTCAACCT-3’ and Rev: 
5’-CAGGAATGGCCAGGATAAAGG-3’; Cyclophilin-A 
Fw: 5’-TTCATCTGCACTGCCAAGAC-3’ and Rev: 
5’-TCGAGTTGTCCACAGTCAGC-3’.
RNA silencing
The ON-TARGETplus HUMAN small interfering 
RNA (siRNA) duplexes SMARTpool used to silence 
β-arr1 or HIF-1α were purchased from Dharmacon (CO, 
USA). The ON-TARGETplus Control pool Non-targeting 
siRNA (Dharmacon, CO, USA) was used as negative 
control. The lentiviral-based shRNAs plasmids (pLKO.1 
plasmids) used to silence β-arr1, purchased from Sigma-
Aldrich S.r.l. (Italy), was used to generate HEY cells stably 
silenced for β-arr1 (sh-β-arr1). Five plasmid clones were 
tested for their knockdown efficiency (TRCN0000230149, 
TRCN0000230147, TRCN0000005160, 
TRCN0000005161, TRCN0000230150). The 22-mer 
targeting sequences that resulted in efficient knockdown 
included TRCN0000230150 (#3) were used for stable 
β-arr1 knockdown. Non-Target shRNA Control Vector-
SHC002 (sh-SCR) (Sigma-Aldrich, Italy) was used as 
negative control.
β-arr1 plasmid and transfection constructs
For exogenous expression of β-arr1, pcDNA3-β-
arr1-FLAG (wild type) plasmid construct, a “wobble” 
mutant construct encoding rat β-arr1 sequences resistant to 
siRNA targeting kindly provided by Dr. Robert Lefkowitz 
(Howard Hughes Medical Institute, Duke University) 
was used. Mutation of Gln-394 in Leu of β-arr1-FLAG 
construct (β-arr1Q394L) was done by using QuickChange 
II XL site-Directed Mutagenesis Kit (Agilent 
Technologies, CA, USA). All constructs were verified 
by sequencing. For transient expression of β-arr11-
FLAG or β-arr1Q394L-FLAG, each constructs were 
transfected in cells using LipofectAMINE 2000 reagent 
(Life Technologies, Italy) following the manufacturer’s 
instructions. Cells transfected with the empty vector 
pCDNA3 were used as control. For their stable expression, 
transfected cells were selected by using 500 μg/ml G418 
sulfate (Calbiochem-Novabiochem Corporation, CA, 
USA). G418-resistant cells were pooled 3 weeks after 
transfection and g/ml of G418. Thereafter cells were 
maintained in media containing 500 g/ml of G418.
Luciferase reporter gene assay
Cells were transiently transfected, using 
Lipofectamine 2000 (Life Technologies, Italy) according 
to manifacturer’s instructions, with HRE luciferase 
construct and VEGF construct containing five functional 
derived from 5’-untranslated region of human VEGF, 
kindly provided by Dr. A. Giaccia (Stanford University 
School of Medicine, Stanford, CA) or with ET-1 promoter 
reporter sequence, spanning -1300 to +230 bp surrounding 
the transcriptional initiation site, and containing a 
functional HRE located at -118 to -125 bp, kindly 
provided by Dr. Z. Zhang (University of California San 
Diego School of Medicine, La Jolla, Ca), and with pCMV-
β-galactosidase vector (Promega). Reporter activity was 
measured using the Luciferase assay system (Promega) 
and normalized to β-galactosidase activity. 
Chromatin immunoprecipitation
Chromatin was extracted from cells (5 × 106) and 
ChIP assays were performed as previously described 
[18]. The differential binding between proteins and 
promoter DNA was examined by PCR. The primary 
Abs used were as follows: HIF-1α (Abcam, UK), β-arr1 
(Santa Cruz Biotechnology CA, USA), p300 (Santa 
Cruz Biotechnology CA, USA) and acetyl-Histone 
3 (AcH3) (BD Laboratory Transduction, NJ, USA). 
The primers used were as follows: ET-1 promoter Fw: 
5′-CAGCTTGCAAAGGGGAAGCG-3′ and Rev: 
5′-TCCGACTTTATTCCAGCCCC-3’; VEGF promoter 
Fw: 5’-AGGAACAAGGGCCTCTGTCT-3’ and Rev: 
5’-CAGTGTGTCCCTCTGACAATG-3’.
Chemotaxis and chemoinvasion assay
Cell chemotaxis and chemoinvasion assays were 
carried out using modified Boyden Chambers consisting 
of transwell membrane filter inserts with 8 μm syze 
polycarbonate membrane (chemotaxis) or precoated 
with polymerized Cultrex (basal membrane extract; 
Trevigen, MD, USA; chemoinvasion) placed in a 24-well 
plate (Sigma-Aldrich, Italy). For the chemotaxis assay 
conditioned medium (RPMI) from HEY cells, served as 
chemoattractant in the lower compartment. The HUVEC 
were added to the chamber with polycarbonate membrane 
and left to migrate for 24 h at 37°C. For the chemoinvasion 
assay ET-1 was used as chemoattractant. The cells were 
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added to the invasion chamber and incubated for 24 h at 
37°C. Cells on the underside of the membrane were fixed, 
stained with the Diff-Quik staining kit (BD Biosciences) 
and counted using a light microscope. From every 
transwell assay, representative images were captured with 
Olympus 1X70 at 20x magnification and two broad fields 
were considered for quantification.
Tubule-like structure formation
The ability of HUVEC cells, cultured in conditioned 
medium (RPMI) from HEY cells with or without MAC, 
to form capillary-like structure formation has been 
assessed on cells cultured on Cultrex (basal membrane 
extract; Trevigen, MD, USA). Images were analyzed with 
ImageJ v.1.34s (http://rsb.info.nih.gov/ij/) for determining 
the length of the tubes and the number of intersections. 
Representative images were captured with Olympus 1X70 
microscope at 20x magnification and two fields were 
considered for quantification. 
ELISA
The release of ET-1 and VEGF in the conditioned 
media of serum-starved cells was measured on microtiter 
plates by ET-1 ELISA kit and by Quantikine human VEGF 
immunoassay kit (R&D Systems, MN, USA) according to 
the manufacturer’s instructions. 
In vivo assays
For metastasis assay, 1.8x106 parental HEY cells or 
clonally derived HEY cells stably expressing sh-SCR, or 
sh-β-arr1, or sh-β-arr1 rescued with β-arr1 or β-arr1Q394L 
expressing vectors, were injected intraperitoneally into 
female athymic (nu+/nu+) mice 4-6 weeks of age (Charles 
River Laboratories, Milan, Italy). In all experiments, each 
group consisted of 10 mice. Two weeks after mice were 
inoculated with parental HEY cells, they were treated 
with (i) vehicle and (ii) macitentan (30 mg/kg, oral 
daily). At the end of treatment, all mice were sacrificed 
and intraperitoneal organs were analysed. The number of 
visible metastases was counted. 
Intravasation assays
Mice injected with clonally derived cells HEY 
stably expressing SCR, or sh-β-arr1, or sh-β-arr1 rescued 
with β-arr1Q394L expression vector were perfused 
with 5 ml PBS through the left ventricle. 1 ml of blood 
perfused was collected from the atrium and lysed twice 
with Red Blood Cell (RBC) lysis buffer. Total RNA 
was extracted from the remaining cells and used for 
qRT-PCR. The presence of circulating tumor cells 
was determined by the relative expression of human-
specific GAPDH normalized to murine β-actin. GAPDH 
Fw: 5’-GTGAAGGTCGGAGTCAACG-3’ and Rev: 
5’-GGTGAAGACGCCAGTGGACTC-3’; β-actin 
Fw: 5’-CGATGCCCTGAGGCTCTTT-3’ and Rev: 
5’-TAGTTTCATGGATGCCACAGGAT-3’.
Statistical analysis
Each experiment was repeated at least three times 
with comparable results, unless indicated otherwise. 
Results are expressed as means ± S.D. Statistical analysis 
was performed using Student’s t test and Fisher’s exact 
test as appropriate. All statistical tests were carried out 
using the SPSS software (SPSS II, SPSS Inc., IL, USA). 
A two-sided probability value of < 0.05 was considered 
statistically significant.
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